Dubsky, PC; Fesl, C; Singer, CF; Pfeiler, G; Kronenwett, R; Hubalek, M; Bartsch, R; Stoeger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Tea, MKM; Wette, V; Petzner, AL; Sevelda, P; Egle, D; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Lax, S; Regitnig, P; Gnant, M; Filipits, M.
The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34
CANCER RES. 2018; 78(4):-San Antonio Breast Cancer Symposium; DEC 05-09, 2017; San Antonio, TX.
[Oral Communication]
Web of Science